GSTP1 and metabolic dysfunction-associated steatotic liver disease: It is likely that the phenotype of GSTP1 overexpression in NAFLD patients is multifaceted, but could involve chemotherapeutic resistance in hepatic tumors, and conversely protection from hepatotoxicity for noncancerous liver tissue.